NCT03067857

Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease

Autologous Purified Bone-Marrow-Derived Stem Cell Therapy for Motor Neuron Disease

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Stem Cells Arabia · Academic / Other
• Sex: All
• Age: 24 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Herein, the investigators study the safety and efficacy of transplanting purified autologous bone marrow-derived stem cells transplanted via the intrathecal route by interventional radiology and the intravenous route.

Detailed description

A motor neuron disease (MND) is any of several neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body. They include amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), progressive bulbar palsy (PBP) and pseudobulbar palsy; spinal muscular atrophies are also sometimes included in the group.They are neurodegenerative diseases that cause increasing disability and eventually, death. In spite of intensive research, motor neuron diseases (MNDs) are still incurable. Some of the key factors in this failure to find a cure have been the lack of human cell-based disease models for molecular analysis and drug screening and the difficulty of obtaining homogeneous populations of specific cell types for clinical applications. Stem cell biology has the potential to transform our understanding of disease processes and to revolutionize our approach to develop novel therapies for MNDs. In this study, the investigators suggest a protocol for the treatment of MND by transplantation of purified autologous bone marrow-derived stem cells via the intrathecal and intravenous route.

Conditions

• Motor Neuron Disease
• Amyotrophic Lateral Sclerosis
• Primary Lateral Sclerosis
• Progressive Muscular Atrophy
• Progressive Bulbar Palsies

Interventions

Type	Name	Description
BIOLOGICAL	Stem Cells	Autologous bone marrow-derived stem cell populations injected via the intravenous and intrathecal routes.

Timeline

• Start date: 2016-09-01
• Primary completion: 2019-01-01
• Completion: 2019-08-01
• First posted: 2017-03-01
• Last updated: 2018-06-06